AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7704350 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy volunteers in a clinical trial
Number of subjects: 300
Study 7704350 — intervention group
Group type: COMPARATOR
Intervention: Breast cancer patients in a clinical trial
Number of subjects: 300
Study 3138609 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose animal antigen injection
Number of subjects: 21
Study 3138609 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin pretreatment
Number of subjects: 21
Study 29868833 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue ART (CTART)
Number of subjects: 1652
Study 29868833 — intervention group
Group type: COMPARATOR
Intervention: Discontinue ART (DCART)
Number of subjects: 1652
Study 28973650 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of 0.25% bupivacaine with 150 μg clonidine (clonidine group, n = 116)
Number of subjects: 225
Study 28973650 — intervention group
Group type: COMPARATOR
Intervention: 20 mL of 0.25% bupivacaine alone (control group, n = 109)
Number of subjects: 225
Study 26519614 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction plus treatment as usual
Number of subjects: 55
Study 26519614 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual only
Number of subjects: 55
Study 24480956 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg of ramosetron
Number of subjects: 196
Study 24480956 — intervention group
Group type: COMPARATOR
Intervention: 0.075 mg of palonosetron
Number of subjects: 196
Study 22051893 — intervention group
Group type: EXPERIMENTAL
Intervention: Full attention in the left visual field (LVF)
Number of subjects: 0
Study 22051893 — intervention group
Group type: EXPERIMENTAL
Intervention: Full attention in the right visual field (RVF)
Number of subjects: 0
Study 22051893 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor attention in the left visual field (LVF)
Number of subjects: 0
Study 22051893 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor attention in the right visual field (RVF)
Number of subjects: 0
Study 21149771 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour daily patching of the sound eye
Number of subjects: 88
Study 21149771 — intervention group
Group type: COMPARATOR
Intervention: 5 sessions of acupuncture weekly
Number of subjects: 88
Study 17717119 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric resistance training (Con)
Number of subjects: 21
Study 17717119 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric resistance training (Ecc)
Number of subjects: 21
Study 16110015 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2
Number of subjects: 449
Study 16110015 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel 175 mg/m2
Number of subjects: 449
Study 11931319 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharply filtered bands of speech presented at various signal-to-noise ratios (SNRs) ranging from -25 to 41 dB.
Number of subjects: 100
Study 11931319 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired bands of speech with one band held constant while varying the level and SNR of the other band.
Number of subjects: 100
Study 10064757 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic treatment
Number of subjects: 60
Study 10064757 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 60
Study 8540115 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital rectal examination (DRE) + transrectal ultrasonography (TRUS)
Number of subjects: 2730
Study 8540115 — intervention group
Group type: COMPARATOR
Intervention: Prostate-specific antigen (PSA)
Number of subjects: 2730
Study 2399915 — intervention group
Group type: EXPERIMENTAL
Intervention: 100/serum creatinine
Number of subjects: 136
Study 2399915 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine clearance estimated by the Cockcroft and Gault formula
Number of subjects: 136
Study 2399915 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneously measured creatinine clearance
Number of subjects: 136
Study 6902630 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic penicillin
Number of subjects: 57
Study 6902630 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound irrigation and debridement
Number of subjects: 57
Study 6902630 — intervention group
Group type: EXPERIMENTAL
Intervention: Suturing wounds
Number of subjects: 57
Study 6902630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultures of wounds
Number of subjects: 57
Study 6902630 — intervention group
Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus
Number of subjects: 57
Study 30874295 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Reported Neglect Scale (SRNS)
Number of subjects: 2443
Study 31840075 — intervention group
Group type: EXPERIMENTAL
Intervention: Winning Swiss citizenship in the referendum
Number of subjects: 0
Study 31840075 — intervention group
Group type: COMPARATOR
Intervention: Losing Swiss citizenship in the referendum
Number of subjects: 0
Study 27423977 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Intervention (NI)
Number of subjects: 41
Study 27423977 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 41
Study 26035724 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration (WBV) combined with Balance Coordination Exercises (BCEs)
Number of subjects: 42
Study 26035724 — intervention group
Group type: COMPARATOR
Intervention: Home-based Balance Coordination Exercises (BCEs)
Number of subjects: 42
Study 24695721 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (60 mg/d; 20 mg t.i.d.)
Number of subjects: 20
Study 24695721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 22330092 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 539
Study 22330092 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing cigarette consumption
Number of subjects: 539
Study 22330092 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitting smoking
Number of subjects: 539
Study 22330092 — intervention group
Group type: COMPARATOR
Intervention: Health education
Number of subjects: 539
Study 22330092 — intervention group
Group type: COMPARATOR
Intervention: Motivational interviewing
Number of subjects: 539
Study 19737998 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus cisplatin (AC)
Number of subjects: 1725
Study 19737998 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin (GC)
Number of subjects: 1725
Study 19737998 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus cisplatin (AC) in nonsquamous NSCLC subgroup
Number of subjects: 1725
Study 19737998 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin (GC) in nonsquamous NSCLC subgroup
Number of subjects: 1725
Study 19737998 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus cisplatin (AC) in squamous cell histology subgroup
Number of subjects: 1725
Study 19737998 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin (GC) in squamous cell histology subgroup
Number of subjects: 1725
Study 17992118 — intervention group
Group type: COMPARATOR
Intervention: Metronomic chemotherapy (arm A: trofosfamide 50 mg orally three times daily, day 1+)
Number of subjects: 76
Study 17992118 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined anti-inflammatory/angiostatic treatment (arm B: trofosfamide as above plus rofecoxib 25 mg orally, day 1+, and pioglitazone 60 mg orally, day 1+)
Number of subjects: 76
Study 17992118 — intervention group
Group type: COMPARATOR
Intervention: Metronomic chemotherapy (arm A)
Number of subjects: 76
Study 17992118 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined anti-inflammatory/angiostatic treatment (arm B)
Number of subjects: 76
Study 15224207 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of rosiglitazone (4 mg b.i.d.) to gliclazide (160 mg/day)
Number of subjects: 471
Study 15224207 — intervention group
Group type: COMPARATOR
Intervention: Uptitration of gliclazide to a maximum of 320 mg/day
Number of subjects: 471
Study 11786526 — intervention group
Group type: EXPERIMENTAL
Intervention: LY333531 (protein kinase Cbeta inhibitor)
Number of subjects: 0
Study 11786526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9849243 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal suctioning based on assessment
Number of subjects: 0
Study 9849243 — intervention group
Group type: COMPARATOR
Intervention: Routine endotracheal suctioning every 2 hours
Number of subjects: 0
Study 7926075 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser laparoscopic surgery (laser ablation of endometriotic deposits and laparoscopic uterine nerve ablation)
Number of subjects: 63
Study 7926075 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 63
Study 1522926 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling catheter for 48 hours (group 1)
Number of subjects: 61
Study 1522926 — intervention group
Group type: COMPARATOR
Intervention: Catheterisation on indication only (group 2)
Number of subjects: 61
Study 390528 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of atenolol daily
Number of subjects: 5
Study 390528 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of atenolol daily
Number of subjects: 5
Study 390528 — intervention group
Group type: COMPARATOR
Intervention: 0 mg of atenolol daily (control)
Number of subjects: 5
Study 390528 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (various doses)
Number of subjects: 5
Study 390528 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (25 mg daily)
Number of subjects: 5
Study 30201237 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine plus ketamine (0.1 mg/kg morphine plus 0.2 mg/kg ketamine)
Number of subjects: 200
Study 30201237 — intervention group
Group type: COMPARATOR
Intervention: Morphine plus placebo (0.1 mg/kg morphine plus normal saline)
Number of subjects: 200
Study 29206237 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet (LCD)
Number of subjects: 66
Study 29206237 — intervention group
Group type: COMPARATOR
Intervention: Calorie Restricted Diet (CRD)
Number of subjects: 66
Study 25781440 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued thienopyridine for 18 months after 12 months of DAPT
Number of subjects: 11648
Study 25781440 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 18 months after 12 months of DAPT
Number of subjects: 11648
Study 25781440 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued thienopyridine for 18 months after 12 months of DAPT (all patients)
Number of subjects: 11648
Study 25781440 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 18 months after 12 months of DAPT (all patients)
Number of subjects: 11648
Study 23872799 — intervention group
Group type: EXPERIMENTAL
Intervention: IV pamidronate (1 mg/kg)
Number of subjects: 24
Study 23872799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 21769048 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline (500 mg twice daily)
Number of subjects: 29
Study 21769048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 19254614 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking with a walking cane
Number of subjects: 20
Study 19254614 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle foot orthosis
Number of subjects: 20
Study 19254614 — intervention group
Group type: EXPERIMENTAL
Intervention: Slider shoe
Number of subjects: 20
Study 19254614 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all 3 devices
Number of subjects: 20
Study 19254614 — intervention group
Group type: COMPARATOR
Intervention: Walking with no device (control condition)
Number of subjects: 20
Study 18645758 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Quality Assurance (IQA) training
Number of subjects: 70
Study 18645758 — intervention group
Group type: COMPARATOR
Intervention: Workshop Only (WSO)
Number of subjects: 70
Study 15106798 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline daytime ambulatory blood pressure
Number of subjects: 295
Study 15106798 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up clinic blood pressure after 6 months
Number of subjects: 295
Study 15106798 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal systolic daytime ambulatory blood pressure at baseline
Number of subjects: 295
Study 15106798 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal follow-up clinic blood pressure
Number of subjects: 295
Study 15106798 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of cardiovascular events
Number of subjects: 295
Study 11771971 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg paroxetine
Number of subjects: 6
Study 11771971 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg paroxetine
Number of subjects: 6
Study 11771971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 9640900 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention program for parents (manual-guided program during the first six months following diagnosis)
Number of subjects: 81
Study 9640900 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 81
Study 7857486 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAVELPILOT IDS navigation system
Number of subjects: 48
Study 7857486 — intervention group
Group type: COMPARATOR
Intervention: Conventional road map
Number of subjects: 48
Study 2492744 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (74 mumol.kg‐1.d‐1) during 11 postoperative days
Number of subjects: 16
Study 2492744 — intervention group
Group type: COMPARATOR
Intervention: Carnitine-free total parenteral nutrition (TPN)
Number of subjects: 16
Study 982547 — intervention group
Group type: EXPERIMENTAL
Intervention: Suramin (4-6 g)
Number of subjects: 96
Study 982547 — intervention group
Group type: EXPERIMENTAL
Intervention: Suramin followed by diethylcarbamazine (6-7 days)
Number of subjects: 96
Study 982547 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 96
Study 11561266 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL of mepivacaine (Group I)
Number of subjects: 89
Study 11561266 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of mepivacaine (Group II)
Number of subjects: 89
Study 11561266 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL twice with an interval of 5 minutes (Group III)
Number of subjects: 89
Study 11561266 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL twice with an interval of 10 minutes (Group IV)
Number of subjects: 89
Study 30667591 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily extended-release tacrolimus tablets (LCPT) 0.07-0.13 mg/kg/day
Number of subjects: 58
Study 30667591 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily immediate-release tacrolimus capsules (IR-Tac) 0.10-0.15 mg/kg/day
Number of subjects: 58
Study 30667591 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily extended-release tacrolimus tablets (LCPT)
Number of subjects: 58
Study 30667591 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily immediate-release tacrolimus capsules (IR-Tac)
Number of subjects: 58
Study 30413507 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital treatment programme (Joint Academy) for 3 months
Number of subjects: 270
Study 30413507 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (BOA) for 3 months
Number of subjects: 270
Study 27387703 — intervention group
Group type: EXPERIMENTAL
Intervention: +0.300 μm spherical aberration
Number of subjects: 10
Study 27387703 — intervention group
Group type: EXPERIMENTAL
Intervention: +0.150 μm spherical aberration
Number of subjects: 10
Study 27387703 — intervention group
Group type: COMPARATOR
Intervention: Negative spherical aberration
Number of subjects: 10
Study 27387703 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no SA induction)
Number of subjects: 10
Study 25191967 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine (MCh) challenge with deep inspirations (DIs) taken immediately after the last dose
Number of subjects: 5
Study 25191967 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine (MCh) challenge with DIs taken 30 minutes after the last dose
Number of subjects: 5
Study 25191967 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo assessment of airway smooth muscle (ASM) shortening during a progressive decrease of carbachol concentration
Number of subjects: 5
Study 22718089 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalent rLP2086 vaccine (200 μg dose)
Number of subjects: 99
Study 22718089 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalent rLP2086 vaccine (60 μg dose)
Number of subjects: 99
Study 22718089 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalent rLP2086 vaccine (20 μg dose)
Number of subjects: 99
Study 22718089 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalent rLP2086 vaccine
Number of subjects: 99
Study 22718089 — intervention group
Group type: COMPARATOR
Intervention: hepatitis A vaccine/placebo control
Number of subjects: 99
Study 20584541 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Self Management (PSM)
Number of subjects: 28
Study 20584541 — intervention group
Group type: COMPARATOR
Intervention: Patient Self Testing (PST)
Number of subjects: 28
Study 17368623 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg/day orally)
Number of subjects: 21
Study 16149143 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon-α2b (10 MU daily for 3 weeks, then 5 MU/TIW) plus ribavirin (1,000-1,200 mg/d) for 21 weeks, continued until week 48 if negative HCV RNA PCR.
Number of subjects: 70
Study 12195931 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg THC
Number of subjects: 8
Study 12195931 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg THC
Number of subjects: 8
Study 12195931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9469743 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal-airway volume (measured by acoustic rhinometry)
Number of subjects: 0
Study 9469743 — intervention group
Group type: EXPERIMENTAL
Intervention: Body temperature
Number of subjects: 0
Study 7703820 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual treatment for partners of drinkers
Number of subjects: 23
Study 7703820 — intervention group
Group type: EXPERIMENTAL
Intervention: Group treatment for partners of drinkers
Number of subjects: 23
Study 7703820 — intervention group
Group type: COMPARATOR
Intervention: No-treatment waiting list control
Number of subjects: 23
Study 2469579 — intervention group
Group type: EXPERIMENTAL
Intervention: ZK 36374 (prostacyclin analogue)
Number of subjects: 32
Study 2469579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 2469579 — intervention group
Group type: EXPERIMENTAL
Intervention: ZK 36374
Number of subjects: 32
Study 2469579 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma camera and whole body monitor
Number of subjects: 32
Study 786665 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine 600 mg daily, 3 days a week for 6 months
Number of subjects: 69
Study 786665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 31995214 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral health‐virtual patient navigation program (video contact in ED and telephonic outreach 24 to 72 hours after discharge, then weekly for up to 45 days)
Number of subjects: 637
Study 31995214 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no virtual patient navigation program)
Number of subjects: 637
Study 31995214 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral health‐virtual patient navigation program
Number of subjects: 637
Study 31995214 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 637
Study 30696474 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to light sedation target (Richmond Agitation-Sedation Scale of -3 to 0)
Number of subjects: 5719
Study 30696474 — intervention group
Group type: EXPERIMENTAL
Intervention: Board-certified intensivists on morning and afternoon shifts
Number of subjects: 5719
Study 30696474 — intervention group
Group type: EXPERIMENTAL
Intervention: Target sedation levels
Number of subjects: 5719
Study 27633813 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior turbinoplasty (ATP)
Number of subjects: 60
Study 27633813 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 60
Study 27633813 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucous radial diode laser ablation (DLA)
Number of subjects: 60
Study 26782852 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity functional exercise program
Number of subjects: 186
Study 26782852 — intervention group
Group type: COMPARATOR
Intervention: Seated control activity
Number of subjects: 186
Study 25052850 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based counselling intervention by trained volunteers
Number of subjects: 5240
Study 22594305 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium (20 mg daily) for 4 weeks
Number of subjects: 350
Study 22594305 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI-resistant LPRD patients
Number of subjects: 350
Study 22594305 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls matched for age and sex
Number of subjects: 350
Study 19383241 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus rhythm control with aspirin (group 1)
Number of subjects: 534
Study 19383241 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus rhythm control with warfarin (group 2)
Number of subjects: 534
Study 19383241 — intervention group
Group type: COMPARATOR
Intervention: Ventricular rate control (group 3)
Number of subjects: 534
Study 17447980 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% calcipotriol cream
Number of subjects: 27
Study 17447980 — intervention group
Group type: COMPARATOR
Intervention: Moisturizing cream
Number of subjects: 27
Study 15135698 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved HR at rest (quartiles: 44 to 69, 70 to 78, 79 to 87, 88 to 148 beats/min)
Number of subjects: 680
Study 15135698 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved exercise HR (quartiles: 53 to 82, 83 to 92, 93 to 106, 107 to 220 beats/min)
Number of subjects: 680
Study 15135698 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved HR at rest
Number of subjects: 680